Michelle Samuel1,2, Michal Abrahamowicz1,2, Jacqueline Joza3, Marie-Eve Beauchamp1, Vidal Essebag3, Louise Pilote1,4. 1. Centre for Outcomes Research and Evaluation, Research Institute of McGill University Health Centre, Montreal, Canada. 2. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada. 3. Division of Cardiology, McGill University Health Centre, Montreal, Canada. 4. Division of General Internal Medicine, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec H4A 3JI, Canada.
Abstract
AIMS: Randomized trials suggest reductions in all-cause mortality and heart failure (HF) rehospitalizations with catheter ablation (CA) in patients with atrial fibrillation (AF) and HF. Whether these results can be replicated in a real-world population with long-term follow-up or varies over time is unknown. We sought to evaluate the long-term effectiveness of CA in reducing the incidence of all-cause mortality, HF hospitalizations, stroke, and major bleeding in AF-HF patients. METHODS AND RESULTS: In a cohort of patients newly diagnosed with AF-HF in Quebec, Canada (2000-2017), CA patients were matched 1:2 to controls on time and frequency of hospitalizations. Confounders were controlled for using inverse probability of treatment weighting. Multivariable Cox models adjusted for the presence of cardiac electronic implantable devices and medication use during follow-up, and the effect of time since CA was modelled with B-splines. For non-fatal outcomes, the Lunn-McNeil approach was used to account for the competing risk of death. Among 101 933 AF-HF patients, 451 underwent CA and were matched to 899 controls. Over a median follow-up of 3.8 years, CA was associated with a statistically significant reduction in all-cause mortality [hazard ratio 0.4 (95% confidence interval 0.2-0.7)], but no difference in stroke or major bleeding. The hazard of HF rehospitalization for CA patients, relative to non-CA patients, varied with time since CA (P = 0.01), with a reduction in HF rehospitalizations until approximately 3 years post-CA. CONCLUSION: Compared with matched non-CA patients, CA was associated with a long-term reduction in all-cause mortality and a reduction in HF rehospitalizations until 3 years post-CA. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Randomized trials suggest reductions in all-cause mortality and heart failure (HF) rehospitalizations with catheter ablation (CA) in patients with atrial fibrillation (AF) and HF. Whether these results can be replicated in a real-world population with long-term follow-up or varies over time is unknown. We sought to evaluate the long-term effectiveness of CA in reducing the incidence of all-cause mortality, HF hospitalizations, stroke, and major bleeding in AF-HFpatients. METHODS AND RESULTS: In a cohort of patients newly diagnosed with AF-HF in Quebec, Canada (2000-2017), CA patients were matched 1:2 to controls on time and frequency of hospitalizations. Confounders were controlled for using inverse probability of treatment weighting. Multivariable Cox models adjusted for the presence of cardiac electronic implantable devices and medication use during follow-up, and the effect of time since CA was modelled with B-splines. For non-fatal outcomes, the Lunn-McNeil approach was used to account for the competing risk of death. Among 101 933 AF-HFpatients, 451 underwent CA and were matched to 899 controls. Over a median follow-up of 3.8 years, CA was associated with a statistically significant reduction in all-cause mortality [hazard ratio 0.4 (95% confidence interval 0.2-0.7)], but no difference in stroke or major bleeding. The hazard of HF rehospitalization for CA patients, relative to non-CA patients, varied with time since CA (P = 0.01), with a reduction in HF rehospitalizations until approximately 3 years post-CA. CONCLUSION: Compared with matched non-CA patients, CA was associated with a long-term reduction in all-cause mortality and a reduction in HF rehospitalizations until 3 years post-CA. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Jason G Andrade; Atul Verma; L Brent Mitchell; Ratika Parkash; Kori Leblanc; Clare Atzema; Jeff S Healey; Alan Bell; John Cairns; Stuart Connolly; Jafna Cox; Paul Dorian; David Gladstone; M Sean McMurtry; Girish M Nair; Louise Pilote; Jean-Francois Sarrazin; Mike Sharma; Allan Skanes; Mario Talajic; Teresa Tsang; Subodh Verma; D George Wyse; Stanley Nattel; Laurent Macle Journal: Can J Cardiol Date: 2018-11 Impact factor: 5.223
Authors: Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2019-01-28 Impact factor: 24.094
Authors: Michal Abrahamowicz; Lise M Bjerre; Marie-Eve Beauchamp; Jacques LeLorier; Rebecca Burne Journal: Stat Med Date: 2016-01-14 Impact factor: 2.373
Authors: Ross J Hunter; Thomas J Berriman; Ihab Diab; Ravindu Kamdar; Laura Richmond; Victoria Baker; Farai Goromonzi; Vinit Sawhney; Edward Duncan; Stephen P Page; Waqas Ullah; Beth Unsworth; Jamil Mayet; Mehul Dhinoja; Mark J Earley; Simon Sporton; Richard J Schilling Journal: Circ Arrhythm Electrophysiol Date: 2014-01-01
Authors: Louise Pilote; Michal Abrahamowicz; Eric Rodrigues; Mark J Eisenberg; Elham Rahme Journal: Ann Intern Med Date: 2004-07-20 Impact factor: 25.391
Authors: Waqas Ullah; Liang-Han Ling; Sandeep Prabhu; Geoffrey Lee; Peter Kistler; Malcolm C Finlay; Mark J Earley; Simon Sporton; Yaver Bashir; Tim R Betts; Kim Rajappan; Glyn Thomas; Edward Duncan; Andrew Staniforth; Ian Mann; Anthony Chow; Pier Lambiase; Richard J Schilling; Ross J Hunter Journal: Europace Date: 2016-02-03 Impact factor: 5.214